DK2986633T3 - Fremgangsmåder til ekspression af peptider og proteiner - Google Patents

Fremgangsmåder til ekspression af peptider og proteiner Download PDF

Info

Publication number
DK2986633T3
DK2986633T3 DK14721257.5T DK14721257T DK2986633T3 DK 2986633 T3 DK2986633 T3 DK 2986633T3 DK 14721257 T DK14721257 T DK 14721257T DK 2986633 T3 DK2986633 T3 DK 2986633T3
Authority
DK
Denmark
Prior art keywords
gly
ser
leu
asp
ala
Prior art date
Application number
DK14721257.5T
Other languages
English (en)
Inventor
Lutz Schmitt
Christian Schwarz
Sander Hendrikus Joannes Smits
Original Assignee
Numaferm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numaferm Gmbh filed Critical Numaferm Gmbh
Application granted granted Critical
Publication of DK2986633T3 publication Critical patent/DK2986633T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/01—Sulfurtransferases (2.8.1)
    • C12Y208/01008—Lipoyl synthase (2.8.1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (11)

1. Fremgangsmåde til fremstillingen af et rekombinant peptid (PeOI) eller protein af interesse (PrOI), hvor fremgangsmåden omfatter: (a) at indføre et nukleinsyremolekyle, der koder for et fusionsprotein omfattende mindst et PeOI eller PrOI, og mindst en allokrit af et type 1-sekretionssystem (T1SS) eller et fragment deraf, i en værtscelle, hvor værtscellen ikke udtrykker en heterolog ATP-bindende kassette (ABC)-transporter, et heterologt membranfusionsprotein (MFP) og/eller et heterologt ydre membranprotein (OMP) af TISS'et, hvor fragmentet har en længde på mindst 50 nukleotider; (b) at dyrke værtscellen under betingelser, der tillader udtryk af fusionsproteinet, hvor fusionsproteinet udtrykkes i formen af inklusionslegemer (IB); (c) at isolere det rekombinante fusionsprotein fra værtscellerne; og (d) at udsætte det rekombinante fusionsprotein for betingelser, der tillader PeOI eller PrOI at folde til en funktionel tredimensionel konformation.
2. Fremgangsmåden ifølge krav 1, hvor allokritten af et T1SS vælges fra gruppen bestående af HlyA, CyaA, EhxA, LktA, PILktA, PasA, PvxA, MmxA, LtxA, ApxIA, ApxIIA, ApxIIIA, ApxIVA, Apxl, Apxll, AqxA, VcRtxA, VvRtxA, MbxA, RTX cytotoxin, RtxLl, RtxL2, FrhA, LipA, TliA, PrtA, PrtSM, PrtG, PrtB, PrtC, AprA, AprX, ZapA, ZapE, Sap, HasA, colicin V, LapA, ORF, RzcA, RtxA, XF2407, XF2759, RzcA, RsaA, Crs, CsxA, CsxB, SlaA, SwmA, SI 11951, NodO, PlyA, PlyB, FrpA, FrpC.
3. Fremgangsmåden ifølge krav 1 eller 2, hvor allokritten af et T1SS er HlyA omfattende eller bestående af aminosyresekvensen som fremsat i SEQ ID NO:2, et fragment deraf eller et polypeptid, der har mindst 80 % sekvensidentitet til aminosyresekvensen af SEQ ID NO:2 eller fragmentet deraf.
4. Fremgangsmåden ifølge krav 3, hvor fragmentet af HlyA består af aminosyresekvensen som fremsat i SEQ ID NO:4 eller et polypeptid, der har mindst 80 % sekvensidentitet til aminosyresekvensen af SEQ ID NO:4.
5. Fremgangsmåden ifølge et hvilket som helst af kravene 1-4, hvor udtryksmediet omfatter 20,0 mM eller mindre af Ca2+.
6. Fremgangsmåden ifølge et hvilket som helst af kravene 1-5, hvor udtrykket af det endogene ABC-transportergen, det endogene MFP-gen og/eller det endogene OMP-gen af TISS'et eller aktiviteten af de tilsvarende genprodukter i værtscellen er inhiberet eller transporten er ineffektiv.
7. Fremgangsmåden ifølge krav 6, hvor værtscellen ikke udtrykker endogen ABC-transporter, endogent MFP og/eller endogent OMP af TISS'et.
8. Fremgangsmåden ifølge et hvilket som helst af kravene 1-7, hvor i trin (d) det rekombinante peptid eller protein udsættes for en genfoldnings-buffer, hvor genfoldnings-bufferen omfatter mindst 0,01 mM af Ca2+.
9. Fremgangsmåden ifølge et hvilket som helst af kravene 1-8, hvor: (I) værtscellen er en prokaryotisk celle; og/eller (II) ekspressionen udføres i minimalt dyrkningsmedie; og/eller (III) det rekombinante fusions-peptid eller protein oprenses under anvendelse af en fremgangsmåde valgt fra affinitetskromatografi, ionbytterkromatografi, omvendt-fase kromatografi, størrelseskromatografi, og kombinationer deraf; og/eller (IV) fremgangsmåden omfatter det yderligere trin (e) at bringe det rekombinante fusionsprotein i kontakt med en protease egnet til spaltning af fusionsproteinet for at give allokritten og peptidet eller PrOI som separate molekyler; og/eller (V) fremgangsmåden omfatter det yderligere trin (e) at spalte det rekombinante fusionsprotein ved kemisk behandling for at give allokritten og PeOI eller PrOI som separate molekyler; og/eller (VI) fremgangsmåden omfatter et trin (e) som defineret i (IV) eller (V) efterfulgt af oprensning af PeOI eller PrOI.
10. Fremgangsmåden ifølge et hvilket som helst af kravene 1-9, hvor det mindst ene PeOI eller PrOI vælges fra gruppen bestående af Nisin, HCRF, IFABP, IFNA2, MBP, peptid 101, peptid 102, peptid 103, MAB-40, Mab-42, Fuzeon®, laks-calcitonin, human calcitonin, inhibitorpeptid 1, peptid 238 som fremsat i SEQ ID NO:53, peptid 239 som fremsat i SEQ ID NO:54, peptid 240 som fremsat i SEQ ID NO:55, og peptid 241 som fremsat i SEQ ID NO:56.
11. Fremgangsmåden ifølge et hvilket som helst af kravene 1-10, hvor nukleinsyremolekylet, der koder for fusionsproteinet yderligere omfatter en regulatorisk nukleotidsekvens, der modulerer udtryk af fusionsproteinet.
DK14721257.5T 2013-04-17 2014-04-17 Fremgangsmåder til ekspression af peptider og proteiner DK2986633T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13164098.9A EP2792686A1 (en) 2013-04-17 2013-04-17 Methods for the expression of peptides and proteins
PCT/EP2014/057887 WO2014170430A1 (en) 2013-04-17 2014-04-17 Methods for the expression of peptides and proteins

Publications (1)

Publication Number Publication Date
DK2986633T3 true DK2986633T3 (da) 2018-03-12

Family

ID=48128171

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14721257.5T DK2986633T3 (da) 2013-04-17 2014-04-17 Fremgangsmåder til ekspression af peptider og proteiner

Country Status (13)

Country Link
US (1) US10443081B2 (da)
EP (2) EP2792686A1 (da)
JP (1) JP6714902B2 (da)
CN (1) CN105473609A (da)
AU (1) AU2014255697B2 (da)
CA (1) CA2912300C (da)
DK (1) DK2986633T3 (da)
ES (1) ES2661404T3 (da)
NO (1) NO2986633T3 (da)
PL (1) PL2986633T3 (da)
PT (1) PT2986633T (da)
TR (1) TR201802551T4 (da)
WO (1) WO2014170430A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033622B2 (en) 2017-05-25 2021-06-15 Leidos, Inc. PD-1 and CTLA-4 dual inhibitor peptides
JPWO2020090045A1 (ja) * 2018-10-31 2021-10-14 株式会社村田製作所 抗グラム陰性菌化合物
US11407829B2 (en) 2019-05-22 2022-08-09 Leidos, Inc. LAG3 binding peptides
WO2021185968A1 (en) 2020-03-18 2021-09-23 Numaferm Gmbh Fragments of hlya and uses thereof
EP3892290A1 (en) 2020-04-08 2021-10-13 NUMAFERM GmbH Variants of hlya and uses thereof
EP3882260A1 (en) 2020-03-18 2021-09-22 NUMAFERM GmbH Fragments of hlya and uses thereof
EP4188947A2 (en) 2020-07-31 2023-06-07 Leidos, Inc. Lag3 binding peptides
CN112481225A (zh) * 2021-01-07 2021-03-12 遵义医科大学 一种异源表达卤化酶的纯化方法
WO2022194403A1 (en) 2021-03-18 2022-09-22 Numaferm Gmbh Fusion proteins comprising gg repeat sequences
WO2023108026A2 (en) 2021-12-08 2023-06-15 Oakgrove Bio Llc Biological production of histidine-rich peptides
EP4339202A1 (en) 2022-09-16 2024-03-20 NUMAFERM GmbH Fusion proteins comprising gg repeat sequences ii

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206154A (en) 1985-01-28 1993-04-27 Xoma Corporation Method of producing cecropins by microbiological techniques
US5215896A (en) 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
DE69332740T2 (de) 1992-08-21 2004-02-05 The University Of British Columbia, Vancouver Kationische peptide und verfahren zu deren herstellung
US5648244A (en) 1993-09-27 1997-07-15 President And Fellows Of Harvard College Production, purification, cleavage and use of fusion peptides
US6037145A (en) 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
EP1532261B1 (en) 2002-05-24 2010-02-10 Medtronic, Inc. Methods and dna constructs for high yield production of polypeptides
EP1921149A1 (en) 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
CN101792729B (zh) 2009-12-18 2012-05-30 江南大学 一种高效分泌表达重组角质酶的基因工程菌及其构建方法
EP2583975A1 (en) * 2011-10-21 2013-04-24 Heinrich-Heine-Universität Düsseldorf Agents and methods for the expression and secretion of peptides and proteins

Also Published As

Publication number Publication date
EP2986633B1 (en) 2018-01-31
WO2014170430A1 (en) 2014-10-23
US10443081B2 (en) 2019-10-15
CA2912300C (en) 2023-01-24
EP2986633A1 (en) 2016-02-24
AU2014255697B2 (en) 2017-08-10
BR112015026384A2 (pt) 2017-10-10
PT2986633T (pt) 2018-03-08
JP2016515396A (ja) 2016-05-30
TR201802551T4 (tr) 2018-03-21
BR112015026384A8 (pt) 2018-05-22
ES2661404T3 (es) 2018-03-28
CN105473609A (zh) 2016-04-06
NO2986633T3 (da) 2018-06-30
AU2014255697A1 (en) 2015-12-03
EP2792686A1 (en) 2014-10-22
JP6714902B2 (ja) 2020-07-01
PL2986633T3 (pl) 2018-06-29
US20160138066A1 (en) 2016-05-19
CA2912300A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
DK2986633T3 (da) Fremgangsmåder til ekspression af peptider og proteiner
US10662231B2 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
US9493804B2 (en) Agents and methods for the expression and secretion of peptides and proteins
KR20170085129A (ko) 펩티드 생산용 융합 파트너
CN111363048B (zh) 一种具有穿膜活性的可溶性重组苦荞金属硫蛋白FtMT及其制备方法
JP7266325B2 (ja) 蛍光タンパク質フラグメントを含む融合タンパク質およびその用途
KR101373297B1 (ko) 대장균 포스포글리세르산 인산화효소 유전자를 융합 파트너로서 포함하는 발현벡터
JP7016552B2 (ja) 組換えタンパク質の分泌を増加させる方法
Wojtowicz-Krawiec et al. Use of Ubp1 protease analog to produce recombinant human growth hormone in Escherichia coli
KR100368073B1 (ko) 융합파트너를 이용한 재조합 단백질의 제조방법
KR101443920B1 (ko) 시스토비루스 ｐｈｉ6의 외피막 단백질 Ｐ9을 융합파트너로포함하는 막 단백질 발현벡터 및 이를 이용한 막 단백질의생산방법
EP4308704A1 (en) Fusion proteins comprising gg repeat sequences
WO2022194375A1 (en) Fusion proteins comprising gg repeat sequences
KR101505697B1 (ko) 시스토바이러스 파이12의 외피막 단백질 피9을 융합파트너로 포함하는 막 단백질 발현벡터 및 이를 이용한 막 단백질 제조 방법
BR112015026384B1 (pt) Método para produzir peptídeo recombinante (peoi) ou proteína de interesse (proi)
WO2013127752A1 (en) Method for reduction of 1->3 reading frame shifts
RU2801248C2 (ru) Гибридный белок, содержащий фрагменты флуоресцентных белков, и его применение
Makkapati Recombinant production of peptides using SUMO as a fusion partner